跳至主要内容
临床试验/NCT04342676
NCT04342676已完成3 期

Lymph Node Ratio and Kras Mutation in Risk Stratification of Colon Cancer

Mansoura University1 个研究点 分布在 1 个国家目标入组 433 人开始时间: 2017年3月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
433
试验地点
1
主要终点
LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).

研究概览

简要总结

clinical impact of LN ratio with Kras expression in colon cancer

详细描述

LNR and K ras were evaluated with correlated with different clinicopathological parameters of the patients, PFS and OS.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
16 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Stage III colon cancer

排除标准

  • Stage I, II, IV

研究组 & 干预措施

patients

Experimental

LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )

干预措施: k ras (Device)

patients

Experimental

LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )

干预措施: Panitumumab (Drug)

结局指标

主要结局

LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).

时间窗: 2 years

impact on response

次要结局

  • LNR and K ras were evaluated and ASSOCIATION with PFS and OS.(2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Lymph Node Ratio and Kras Mutation in R Colon Cancer | 临床试验